US Patent

US9669033 — Selective PI3K delta inhibitors

Method of Use · Assigned to Rhizen Pharmaceuticals AG · Expires 2033-07-02 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods of treatment and/or prevention of kinase-mediated diseases or disorders using selective inhibitors of PI3K delta protein kinases.

USPTO Abstract

The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3063`	—	umbralisib-tosylate

Patent Metadata

Patent number: US9669033
Jurisdiction: US
Classification: Method of Use
Expires: 2033-07-02
Drug substance claim: No
Drug product claim: No
Assignee: Rhizen Pharmaceuticals AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.